1
|
Qin A, Wu D, Liao J, Xie S, Chen H, Gao Y, Cui J, Su X, Miyachi N, Sato T, Li Y, Zhang J, Shen W, Wang W. Ethnic sensitivity analyses of pharmacokinetics, efficacy and safety in polycythemia vera treatment with ropeginterferon alfa-2b. Front Pharmacol 2024; 15:1455979. [PMID: 39386026 PMCID: PMC11463156 DOI: 10.3389/fphar.2024.1455979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2024] [Accepted: 08/27/2024] [Indexed: 10/12/2024] Open
Abstract
Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the pharmacokinetics (PK), efficacy, and safety profiles across diverse ethnic groups. We conducted a relevant review of PV and analysis of data obtained from clinical studies involving Ropeg. The PK behavior of ropeg showed no significant differences between Chinese and overseas populations. Their efficacy and safety profiles were similar across the ethnic groups. The analyses indicated that the dose-exposure-response profile of Ropeg was consistent irrespective of ethnic variations. The results suggest that Ropeg exhibits a consistent PK and pharmacodynamics profile and a similar therapeutic effect across different ethnic groups, confirming its efficacy and safety in the global treatment of PV. More generally, these findings support the broader application of Ropeg in diverse patient populations and emphasize the need for an inclusive clinical practice.
Collapse
Affiliation(s)
- Albert Qin
- PharmaEssentia Corporation, Taipei, Taiwan
| | - Daoxiang Wu
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China
| | - Jason Liao
- PharmaEssentia Corporation, Taipei, Taiwan
| | - Shuping Xie
- Pharmaron Clinical Services Co., Ltd., Chengdu, China
| | - Haoqi Chen
- Pharmaron Clinical Services Co., Ltd., Chengdu, China
| | - Yucheng Gao
- Pharmaron Clinical Services Co., Ltd., Chengdu, China
| | - Jie Cui
- Pharmaron Clinical Services Co., Ltd., Chengdu, China
| | - Xia Su
- Pharmaron Clinical Services Co., Ltd., Chengdu, China
| | | | | | - Yaning Li
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China
| | - Jingjing Zhang
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China
| | - Weihong Shen
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China
| | - Wei Wang
- PharmaEssentia Biotech (Beijing) Limited, Beijing, China
| |
Collapse
|
2
|
Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020; 42:100714. [DOI: 10.1016/j.blre.2020.100714] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2019] [Revised: 08/02/2019] [Accepted: 05/11/2020] [Indexed: 02/06/2023]
|